ABSTRACT
Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They are characterized by the inability to control the impulse to perform an act that can be detrimental to them or to others. Although dopamine agonists (DA), as a group, have been associated with impulse control disorders (ICD), piribedil has rarely been reported to cause them. Method Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG). Results All of the patients presented ICD associated with piribedil use. Two of them received this medication as first treatment and four of them who had developed ICDs secondary to other DA that reappeared with piribedil. Conclusion Despite piribedil is commercially available in only a few countries, it should be considered in the differential diagnosis of PG in patients with PD. .
Os distúrbios do controle do impulso (DCI) na doença de Parkinson (DP) têm atraído crescente interesse. Eles são caracterizados pela incapacidade da pessoa em controlar o impulso para realizar um ato que pode ser prejudicial a ela própria ou aos outros. Embora os agonistas dopaminérgicos (AD), como um grupo, têm sido associados com distúrbios do controle do impulso, o piribedil tem sido relatado raramente como causa dos mesmos. Método Relatos de seis casos de pacientes parkinsonianos em uso de piribedil apresentando jogo patológico (JP). Resultados Todos os pacientes apresentaram DCI com o uso do piribedil. Dois deles receberam piribedil como primeiro tratamento e quatro deles que haviam desenvolvido DCI devido a outro AD, reapresentaram o quadro com piribedil. Conclusão Apesar de o piribedil estar disponível comercialmente apenas em alguns países, deveria ser considerado no diagnóstico diferencial de JP em pacientes com DP. .
Subject(s)
Animals , Cerebrovascular Circulation/physiology , Homeostasis/physiology , Parietal Lobe/embryology , Blood Pressure/physiology , Embryonic and Fetal Development , Fetus/physiology , Laser-Doppler Flowmetry , Sheep/embryologyABSTRACT
Objective To investigate the clinical effect of prophylactic low dose of escitalopram in patients with depressive symp-toms and overall symptoms of Parkinson′s .Methods 40 patients were divided into single drug group used alone Piribedil and com-bined treatment group used Piribedil and escitalopram ,20 cases in each group .Hamilton depression scale (HAMD) ,Parkinson′s disease questionnaire composite score standard (UPDRS) and 39 Parkinson′s disease questionnaire score (PDQ-39) prior treatment were used to assess the changes of the patients′degree of depression and the Parkinson′s overall symptoms .Results Compared with prior treatment ,the HAMD score in single drug group after two weeks treatment had no significant difference (P> 0 .05) , while in combined treatment group ,the HAMD score decreased significantly (P0 .05) .After six weeks treatment ,Compared with prior treatment ,both in single drug group and combined treatment group ,the HAMD score ,UPDRS score and PDQ-39 score had significantly decreased (P<0 .05) ,but without significant differences between the two groups (P<0 .05) .Conclusion Prophylactic low dose of escitalo-pram may be early control of symptoms of Parkinson′s patients with mild depression .It can also be used to improve the overall symptoms of Parkinson′s patients ,which propose new ideas for the clinical treatment of Parkinson′s disease .
ABSTRACT
Objective:To observe the clinical effect of piribedil and madopar on Parkinson's disease ( PD) . Methods:Totally 58 patients with PD were divided randomly into the treatment group (29 cases) and the control group (29 cases). Piribedil and madopar were used in the treatment group, while only madopar was applied in the control group. Therapeutic effect of both groups was evaluated by UPDRS at the end of 6 courses. Results:The decrease of UPDRS after the remedy in the treatment group was more significant than that in the control group (P<0. 05), and the total effective rate in the treatment group(89. 7%) was significantly higher than that in the control group(65. 5%)(P<0. 05). Conclusion:The clinical effect of piribedil combined with madopar on PD is superior to that of madopar alone, therefore, the combination use is a useful method in the treatment of PD with the value of popularization and applica-tion.